FORM PTO-: 390 , (REV. 10-2003) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTORNEY'S DOCKET NUMBER TRANSMITTAL LETTER TO THE UNITED STATES **DESIGNATED/ELECTED OFFICE (DO/EO/US)** 11245/51003 CONCERNING A FILING UNDER 35 U.S.C. 371 U.S. APPLICATION NO (not),n, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE RIORITY DATE CLAIMED: 21 March 2005 19 March 2004 PCT/US2005/009583 TITLE OF INVENTION HUMAN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY APPLICANT(S) FOR DO/EO/US LIU and ZHU Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. 図 This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. ✓ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. ☑ The US has been elected (Article 31). 5. **☑** A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. \square is attached hereto (required only if not communicated by the International Bureau). b. Dhas been communicated by the International Bureau. c. I is not required, as the application was filed in the United States Receiving Office (RO/US). 6. □ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. \square is attached hereto. b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4). 7. 🗆 Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a \square are attached hereto (required only if not communicated by the International Bureau). b. \square have been communicated by the International Bureau. c. \square have not been made; however, the time limit for making such amendments has NOT expired. d. I have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 8. 9. 🗆 An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (Unsigned) 10. 🗆 An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. Preliminary Amendment.

- 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- 13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
- 14.

 An Application Data Sheet under 37 CFR 1.76.
- 15.

 A substitute specification.
- 16.

 A power of attorney and/or change of address letter.
- 17. ☐ A computer-readable form (one diskette) of the Sequence Listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 1.825, Sequence Listing in paper form (eleven (11) pages) and Sequence Listing Statement.
- 18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
- 19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
- 20. Other items or information: Copy of Published International Application; Sequence Listing in paper form (seven (7) pages) and computer readable form (one (1) diskette); Sequence Listing Statement.

Page 1 of 2

U.S. APPLICATION NO. (if known, see 37 INTERNATIONAL APPLICATION NO. CFR 7.5) 1593804 PCT/US2005/009583 To Be Assigned 11245/51003 THE FILING FEES ARE NOT BEING PAID AT THIS TIME. a. 🗹 SEND ALL CORRESPONDENCE TO: KENYON & KENYON **SIGNATURE** Lawferce P. Cassori NAME One Broadway (Reg. No. 46,606) New York, New York 10004 **CUSTOMER NO. 26646** FORM PTO-1390 (REV 10-2003)

Page 2 of 2